PACT Pharma is an exciting, well-funded clinical-stage biotechnology company developing personalized adoptive T cell therapies for the eradication of solid tumors.
Location: United States, California, South San Francisco
Employees: 201-500
Phone: +1 650-597-9500
Total raised: $75M
Founded date: 2016
Investors 7
| Date | Name | Website |
| - | Vida Ventu... | vidaventur... |
| - | Droia Onco... | droiaventu... |
| - | Taiho Vent... | taihoventu... |
| - | UpHonest C... | uphonestca... |
| - | Canaan Par... | canaan.com |
| - | GV | gv.com |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2020 | Series C | $75M | - |
Mentions in press and media 8
| Date | Title | Description |
| 29.06.2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| 05.03.2021 | PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor | SOUTH SAN FRANCISCO, Calif., March 5, 2021 /PRNewswire/ -- PACT Pharma, Inc., a clinical-stage company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with soli... |
| 05.03.2021 | PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor | |
| 13.01.2020 | PACT Pharma Secures $75M in Series C Financing | PACT Pharma, a SouthSan Francisco, Calif.-based advancing personalized NeoTCR-T cell therapies to eradicate solid tumors, closed a $75m Series C financing. The round was led by Vida Ventures with participation from current investors. As par... |
| 10.01.2020 | PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer | - |
| 22.07.2019 | Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study | “These exciting results open a bold new frontier for directing a person’s own immune system to treat patients with solid cancers, an area that hasn’t yet seen the successes of immune cell therapies that we have seen for blood cancers,” said... |
| 20.09.2017 | Arcus' cancer portfolio attracts $35M option deal from Japan's Taiho | Immuno-oncology startup Arcus Bioscience has signed a deal with Japanese drugmaker Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand. Taiho is paying $35 million over three years for acc... |
| - | Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study | A company developing cell therapies in oncology has started dosing patients in an early-stage clinical trial of a product candidate designed to be targeted to proteins in cancer cells unique to each patient. South San Francisco, California-... |